Lumicera Health Services announced the launch of Clarventa, a new company created to address one of the most persistent drivers of rising prescription drug costs: the complex pharmaceutical supply chain.
Clarventa will focus on bringing greater transparency, efficiency and sustainability to drug purchasing and supply chain services across the pharmacy ecosystem. By creating clearer pathways to access and more predictable purchasing models, Clarventa will help market participants operate with greater confidence in what has become an increasingly complex environment.
“Clarventa is a natural extension of Lumicera’s mission to bring clarity and fairness to how medications are priced and delivered,” Lumicera CEO Ben Heiser said. “We’ve proven that transparent, cost-plus models work in specialty pharmacy. With Clarventa, we’re applying those same principles to drug purchasing and the supply chain—areas where lack of visibility continues to drive unnecessary cost and complexity for pharmacies, manufacturers and, ultimately, patients.”
Clarventa and Lumicera are part of the Navitus Health Solutions family of companies, united by a shared commitment to transparent, patient-focused health care. For nearly 25 years, Navitus Health Solutions has operated as an industry pioneer, challenging conventional models, insisting on clarity and delivering innovative, clinically based solutions that lower costs for members, pan sponsors and health plans.
Navitus founded the first pharmacy benefit manager (PBM) to operate with full transparency and 100% pass-through pricing, rejecting hidden markups and refusing to retain manufacturer rebates. This approach fundamentally challenged traditional PBM practices by aligning incentives with plan sponsors and members rather than drug price inflation.
The same philosophy later extended to specialty pharmacy with the launch of Lumicera, the industry’s first cost-plus specialty pharmacy. Lumicera charges only the actual acquisition cost of medication plus a clearly defined patient management fee, providing clients and members with unprecedented insight into specialty drug costs while maintaining high-touch clinical care.
In 2023, Navitus strengthened its clinical and analytical capabilities in specialty drug management with the acquisition of Archimedes, deepening the organization’s ability to provide oversight, analytics and program design in one of the most complex and expensive areas of health care.
Clarventa builds on this foundation by addressing two other significant sources of cost and complexity: drug purchasing and the pharmaceutical supply chain itself:
- For pharmacies, Clarventa increases access and purchasing power, creating sustainable contracting models.
- For manufacturers and wholesalers, Clarventa enables access through streamlined contracting, producing transparent agreements with clearer data flows.
- For the industry, these improvements align with growing state and federal efforts to promote point-of-sale affordability for health care consumers and consistency in pharmacy reimbursement.
“Pharmacies, manufacturers and wholesalers all play critical roles in patient access, yet too often the system creates friction instead of alignment,” Navitus Health Solutions CEO David Fields said. “Clarventa reduces that friction by bringing clarity to how drugs are priced and purchased, while supporting affordability and fairness. As our industry continues to evolve, Clarventa is an important step in advancing transparency across the drug supply chain.”